<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two proteins, p16INK4A and p14ARF, originating from the same gene locus CDKN2A, use different promoters and alternative reading frames </plain></SENT>
<SENT sid="1" pm="."><plain>p16INK4A is translated from alpha transcript and p14ARF is from beta transcript </plain></SENT>
<SENT sid="2" pm="."><plain>These two proteins, which are inactivated in some human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, are possible <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor candidates </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated the expression of p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNAs</z:chebi> in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We studied eight <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow samples, three reactive <z:hpo ids='HP_0012138'>granulocytic hyperplasia</z:hpo> patients, and 21 haematological <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> patients, including seven <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, four <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, five <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, five <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="5" pm="."><plain>p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was assayed by reverse transcriptase polymerase chain reaction </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> bone marrows and reactive <z:hpo ids='HP_0012138'>granulocytic hyperplasia</z:hpo> showed barely detectable expression of either <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was abnormally increased in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Especially in <z:mp ids='MP_0005481'>CML</z:mp>, overexpression of p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNAs</z:chebi> was more frequent than in controls (80 and 60%, respectively, P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, p16INK4A and p14ARF <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was frequently increased in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, especially in <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>We suggest that overexpression of these <z:chebi fb="2" ids="33699">mRNAs</z:chebi> may be related to the pathogenesis of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
</text></document>